171 related articles for article (PubMed ID: 8195886)
1. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative.
Knuuti MJ; Yki-Järvinen H; Voipio-Pulkki LM; Mäki M; Ruotsalainen U; Härkönen R; Teräs M; Haaparanta M; Bergman J; Hartiala J; Wegelius U; Nuutila P
J Nucl Med; 1994 Jun; 35(6):989-98. PubMed ID: 8195886
[TBL] [Abstract][Full Text] [Related]
2. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols.
Bax JJ; Veening MA; Visser FC; van Lingen A; Heine RJ; Cornel JH; Visser CA
Eur J Nucl Med; 1997 Jan; 24(1):35-41. PubMed ID: 9044874
[TBL] [Abstract][Full Text] [Related]
3. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography.
Knuuti MJ; Nuutila P; Ruotsalainen U; Saraste M; Härkönen R; Ahonen A; Teräs M; Haaparanta M; Wegelius U; Haapanen A
J Nucl Med; 1992 Jul; 33(7):1255-62. PubMed ID: 1613561
[TBL] [Abstract][Full Text] [Related]
4. Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: Comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients.
Bax JJ; Visser FC; Poldermans D; Van Lingen A; Elhendy A; Boersma E; Sloof GW; Visser CA
J Nucl Cardiol; 2002; 9(6):587-93. PubMed ID: 12466782
[TBL] [Abstract][Full Text] [Related]
5. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
6. The value of quantitative analysis of glucose utilization in detection of myocardial viability by PET.
Knuuti MJ; Nuutila P; Ruotsalainen U; Teräs M; Saraste M; Härkönen R; Ahonen A; Wegelius U; Haapanen A; Bergman J
J Nucl Med; 1993 Dec; 34(12):2068-75. PubMed ID: 8254389
[TBL] [Abstract][Full Text] [Related]
7. Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results.
Schröder O; Hör G; Hertel A; Baum RP
Nucl Med Commun; 1998 Sep; 19(9):867-74. PubMed ID: 10581593
[TBL] [Abstract][Full Text] [Related]
8. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.
Vitale GD; deKemp RA; Ruddy TD; Williams K; Beanlands RS
J Nucl Med; 2001 Dec; 42(12):1730-6. PubMed ID: 11752067
[TBL] [Abstract][Full Text] [Related]
9. Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Schinkel AF; Bax JJ; Valkema R; Elhendy A; van Domburg RT; Vourvouri EC; Bountioukos MA; Krenning EP; Roelandt JR; Poldermans D
J Nucl Med; 2003 Jun; 44(6):877-83. PubMed ID: 12791813
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration.
Kam BL; Valkema R; Poldermans D; Bax JJ; Reijs AE; Rambaldi R; Boersma E; Rietveld T; Roelandt JR; Krenning EP
J Nucl Med; 2003 Feb; 44(2):140-5. PubMed ID: 12571201
[TBL] [Abstract][Full Text] [Related]
11. Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium.
Bax JJ; Visser FC; Blanksma PK; Veening MA; Tan ES; Willemsen TM; van Lingen A; Teule GJ; Vaalburg W; Lie KI; Visser CA
J Nucl Med; 1996 Oct; 37(10):1631-6. PubMed ID: 8862297
[TBL] [Abstract][Full Text] [Related]
12. [Appropriate uptake period for myocardial PET imaging with 18F-FDG after oral glucose loading].
Brink I; Nitzsche EU; Mix M; Schindler T; Hentschel M; Högerle S; Moser E
Nuklearmedizin; 2003 Feb; 42(1):39-44. PubMed ID: 12601453
[TBL] [Abstract][Full Text] [Related]
13. The effect of insulin and FFA on myocardial glucose uptake.
Knuuti MJ; Mäki M; Yki-Järvinen H; Voipio-Pulkki LM; Härkönen R; Haaparanta M; Nuutila P
J Mol Cell Cardiol; 1995 Jul; 27(7):1359-67. PubMed ID: 7473782
[TBL] [Abstract][Full Text] [Related]
14. Effect of nicotinic acid on exogenous myocardial glucose utilization.
Stone CK; Holden JE; Stanley W; Perlman SB
J Nucl Med; 1995 Jun; 36(6):996-1002. PubMed ID: 7769458
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of assessing regional myocardial uptake of 18F-fluorodeoxyglucose using single photon emission computed tomography.
Bax JJ; Visser FC; van Lingen A; Huitink JM; Kamp O; van Leeuwen GR; Visser GW; Teule GJ; Visser CA
Eur Heart J; 1993 Dec; 14(12):1675-82. PubMed ID: 8131767
[TBL] [Abstract][Full Text] [Related]
16. Acipimox does not augment thallium-201 redistribution in the fasting state.
Gunning MG; Clunie G; Yepes-Mora S; Eastick S; Underwood SR; Bomanji J; Ell PJ
J Nucl Cardiol; 1999; 6(6):620-5. PubMed ID: 10608589
[TBL] [Abstract][Full Text] [Related]
17. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET.
Ohtake T; Yokoyama I; Watanabe T; Momose T; Serezawa T; Nishikawa J; Sasaki Y
J Nucl Med; 1995 Mar; 36(3):456-63. PubMed ID: 7884509
[TBL] [Abstract][Full Text] [Related]
18. Free fatty acid uptake in the myocardium and skeletal muscle using fluorine-18-fluoro-6-thia-heptadecanoic acid.
Mäki MT; Haaparanta M; Nuutila P; Oikonen V; Luotolahti M; Eskola O; Knuuti JM
J Nucl Med; 1998 Aug; 39(8):1320-7. PubMed ID: 9708500
[TBL] [Abstract][Full Text] [Related]
19. Simple quantification of regional myocardial uptake of fluorine-18-deoxyglucose in the fasting condition.
Tamaki N; Yonekura Y; Kawamoto M; Magata Y; Sasayama S; Takahashi N; Nohara R; Kambara H; Kawai C; Konishi J
J Nucl Med; 1991 Nov; 32(11):2152-7. PubMed ID: 1941154
[TBL] [Abstract][Full Text] [Related]
20. Myocardial 18F-FDG-PET. Experiences with the euglycemic hyperinsulinemic clamp technique.
Locher JT; Frey LD; Seybold K; Jenzer H
Angiology; 1995 Apr; 46(4):313-20. PubMed ID: 7726451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
